"This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public."
This is HCP only content
Further validate the safety and efficacy of Ultimaster™ family DES system in unselected patients representing everyday clinical practice
Further explore the performance of Ultimaster™ family DES in large complex patient and lesions subsets
Prospective, single arm, multi-centre, observational registry
Primary Outcome Measure:
Target Lesion Failure (TLF) defined as a composite of cardiac death, target vessel related Myocardial Infarction (MI)
and clinically driven Target Lesion Revascularization (TLR) at 1 year.
In 25,000+ patients, e-Ultimaster shows 1-year target lesion failure rate of 3.3%.
Primary endpoint: target lesion failure at 1 year
Cardiac death, target-vessel myocardial infarction or clinically-driven target lesion revascularizationn=25'990
Roffi, M., presented at euroPCR2019
Reporting a low target lesion failure rate of 5.2% at 1 year in bifurcation lesions.
1-year clinical outcomesBifurcation, n=3'372 patients
CD-TLR: clinically driven target lesion revascularization; CD-TVR: clinically driven target vessel revascularization; MI: myocardial infarction; ST: definite+probable stent thrombosis; TLF: target lesion failure (a composite of cardiac death, target-vessel MI or CD-TLR)
Chevalier B., presented at euroPCR2019
Providing a safe and good option for the treatment of left main lesions
1-year clinical outcomesLeft main, n=840 patients
LM: left main; MI: myocardial infarction; ST: definite + probable stent thrombosis; TLF: target lesion failure (a composite of cardiac death, target-vessel MI or clinically-driven TLR); TLR: target lesion revascularization; TVF: target vessel failure (composite of cardiac death, target-vessel MI or clinically-driven target-vessel revascularization);
Angioi M.; presented at euroPCR2019
Real-world good clinical outcomes in complex CTO patients.
1-year clinical outcomesChronic total occlusion, n=1309
CD-TLR: clinically-driven target lesion revascularization; MI: myocardial infarction; ST: definite + probable stent thrombosis; TLF: target lesion failure (composite of cardiac death, target vessel MI and CD-TLR); TVF: target vessel failure (composite of cardiac death, target vessel MI and clinically-driven target vessel revascularization
Rumoroso J.; presented at euroPCR2019
Complete revascularization results in good clinical outcomes in all MVD patients and STEMI MVD patients
CD-TLR: clinically-driven target lesion revascularization; MI: myocardial infarction; POCE: patient-oriented composite endpoint ( a composite of all-cause mortality, any MI, any revascularization); ST: definite + probable stent thrombosis; STEMI: ST-elevated myocardial infarction; TLF: target lesion failure (a composite of cardiac death, TV-MI and clinically driven target lesion revascularization)
Hildick-Smith D., presented at euroPCR2019